(19)
(11) EP 2 531 502 A1

(12)

(43) Date of publication:
12.12.2012 Bulletin 2012/50

(21) Application number: 11701856.4

(22) Date of filing: 27.01.2011
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 35/00(2006.01)
 A61K 31/437(2006.01)
(86) International application number:
PCT/GB2011/000106
(87) International publication number:
WO 2011/092469 (04.08.2011 Gazette 2011/31)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 01.02.2010 US 300085 P

(71) Applicants:
  • Cancer Research Technology Limited
    London EC1V 4AD (GB)
  • The Institute of Cancer Research: Royal Cancer Hospital
    London SW7 3RP (GB)

(72) Inventors:
  • SPRINGER, Caroline
    Sutton, Surrey SM2 5NG (GB)
  • NICULESCU-DUVAZ, Ion
    Sutton, Surrey SM2 5NG (GB)
  • MARAIS, Richard
    London SW3 6JB (GB)
  • NICULESCU-DUVAZ, Dan
    Sutton, Surrey SM2 5NG (GB)
  • ZAMBON, Alfonso
    Sutton, Surrey SM2 5NG (GB)
  • MENARD, Delphine
    F-72700 Allonnes (FR)

(74) Representative: Wytenburg, Wilhelmus Johannes et al
Mewburn Ellis LLP 33 Gutter Lane
London EC2V 8AS
London EC2V 8AS (GB)

   


(54) 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY